Tracing the European course of cardiac resynchronization therapy from 2006 to 2008

B. Merkely, Attila Roka, Valentina Kutyifa, Lucas Boersma, Antoine Leenhardt, Andrzej Lubinski, Ali Oto, Alessandro Proclemer, Josep Brugada, Panos E. Vardas, Christian Wolpert

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Cardiac resynchronization therapy (CRT) is a highly efficient treatment modality for patients with severe congestive heart failure and intraventricular dyssynchrony. However, the high individual cost and technical complexity of the implantation may limit its widespread utilization. The European Heart Rhythm Association (EHRA) launched a project to assess treatment of arrhythmias in all European Society of Cardiology member countries in order to have a platform for a progressive harmonization of arrhythmia treatment. As a result, two EHRA White Books have been published in 2008 and 2009 based on governmental, insurance, and professional society data. Our aim was to analyse the local differences in the utilization of CRT, based on these surveys. A total of 41 countries provided enough data to analyse years 2006-2008. Significant differences were found in the overall number of implantations and the growth rate between 2006 and 2008. Other contributing factors include local reimbursement of CRT, the existence of national guidelines, and a high number of conventional implantable cardioverter-defibrillator implantations, while GDP or healthcare spending has less effect. Focusing on improving these factors may increase the availability of CRT in countries where it is currently underutilized.

Original languageEnglish
Pages (from-to)692-701
Number of pages10
JournalEuropace
Volume12
Issue number5
DOIs
Publication statusPublished - 2010

Fingerprint

Cardiac Resynchronization Therapy
Cardiac Arrhythmias
Implantable Defibrillators
Insurance
Therapeutics
Heart Failure
Guidelines
Delivery of Health Care
Costs and Cost Analysis
Growth

Keywords

  • Cardiac resynchronization therapy
  • Europe
  • Implantable cardioverter-defibrillator
  • Pacemaker
  • Reimbursement

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Medicine(all)

Cite this

Merkely, B., Roka, A., Kutyifa, V., Boersma, L., Leenhardt, A., Lubinski, A., ... Wolpert, C. (2010). Tracing the European course of cardiac resynchronization therapy from 2006 to 2008. Europace, 12(5), 692-701. https://doi.org/10.1093/europace/euq041

Tracing the European course of cardiac resynchronization therapy from 2006 to 2008. / Merkely, B.; Roka, Attila; Kutyifa, Valentina; Boersma, Lucas; Leenhardt, Antoine; Lubinski, Andrzej; Oto, Ali; Proclemer, Alessandro; Brugada, Josep; Vardas, Panos E.; Wolpert, Christian.

In: Europace, Vol. 12, No. 5, 2010, p. 692-701.

Research output: Contribution to journalArticle

Merkely, B, Roka, A, Kutyifa, V, Boersma, L, Leenhardt, A, Lubinski, A, Oto, A, Proclemer, A, Brugada, J, Vardas, PE & Wolpert, C 2010, 'Tracing the European course of cardiac resynchronization therapy from 2006 to 2008', Europace, vol. 12, no. 5, pp. 692-701. https://doi.org/10.1093/europace/euq041
Merkely, B. ; Roka, Attila ; Kutyifa, Valentina ; Boersma, Lucas ; Leenhardt, Antoine ; Lubinski, Andrzej ; Oto, Ali ; Proclemer, Alessandro ; Brugada, Josep ; Vardas, Panos E. ; Wolpert, Christian. / Tracing the European course of cardiac resynchronization therapy from 2006 to 2008. In: Europace. 2010 ; Vol. 12, No. 5. pp. 692-701.
@article{93cc7e9368ef420aa0960e1cfe41fb99,
title = "Tracing the European course of cardiac resynchronization therapy from 2006 to 2008",
abstract = "Cardiac resynchronization therapy (CRT) is a highly efficient treatment modality for patients with severe congestive heart failure and intraventricular dyssynchrony. However, the high individual cost and technical complexity of the implantation may limit its widespread utilization. The European Heart Rhythm Association (EHRA) launched a project to assess treatment of arrhythmias in all European Society of Cardiology member countries in order to have a platform for a progressive harmonization of arrhythmia treatment. As a result, two EHRA White Books have been published in 2008 and 2009 based on governmental, insurance, and professional society data. Our aim was to analyse the local differences in the utilization of CRT, based on these surveys. A total of 41 countries provided enough data to analyse years 2006-2008. Significant differences were found in the overall number of implantations and the growth rate between 2006 and 2008. Other contributing factors include local reimbursement of CRT, the existence of national guidelines, and a high number of conventional implantable cardioverter-defibrillator implantations, while GDP or healthcare spending has less effect. Focusing on improving these factors may increase the availability of CRT in countries where it is currently underutilized.",
keywords = "Cardiac resynchronization therapy, Europe, Implantable cardioverter-defibrillator, Pacemaker, Reimbursement",
author = "B. Merkely and Attila Roka and Valentina Kutyifa and Lucas Boersma and Antoine Leenhardt and Andrzej Lubinski and Ali Oto and Alessandro Proclemer and Josep Brugada and Vardas, {Panos E.} and Christian Wolpert",
year = "2010",
doi = "10.1093/europace/euq041",
language = "English",
volume = "12",
pages = "692--701",
journal = "Europace",
issn = "1099-5129",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Tracing the European course of cardiac resynchronization therapy from 2006 to 2008

AU - Merkely, B.

AU - Roka, Attila

AU - Kutyifa, Valentina

AU - Boersma, Lucas

AU - Leenhardt, Antoine

AU - Lubinski, Andrzej

AU - Oto, Ali

AU - Proclemer, Alessandro

AU - Brugada, Josep

AU - Vardas, Panos E.

AU - Wolpert, Christian

PY - 2010

Y1 - 2010

N2 - Cardiac resynchronization therapy (CRT) is a highly efficient treatment modality for patients with severe congestive heart failure and intraventricular dyssynchrony. However, the high individual cost and technical complexity of the implantation may limit its widespread utilization. The European Heart Rhythm Association (EHRA) launched a project to assess treatment of arrhythmias in all European Society of Cardiology member countries in order to have a platform for a progressive harmonization of arrhythmia treatment. As a result, two EHRA White Books have been published in 2008 and 2009 based on governmental, insurance, and professional society data. Our aim was to analyse the local differences in the utilization of CRT, based on these surveys. A total of 41 countries provided enough data to analyse years 2006-2008. Significant differences were found in the overall number of implantations and the growth rate between 2006 and 2008. Other contributing factors include local reimbursement of CRT, the existence of national guidelines, and a high number of conventional implantable cardioverter-defibrillator implantations, while GDP or healthcare spending has less effect. Focusing on improving these factors may increase the availability of CRT in countries where it is currently underutilized.

AB - Cardiac resynchronization therapy (CRT) is a highly efficient treatment modality for patients with severe congestive heart failure and intraventricular dyssynchrony. However, the high individual cost and technical complexity of the implantation may limit its widespread utilization. The European Heart Rhythm Association (EHRA) launched a project to assess treatment of arrhythmias in all European Society of Cardiology member countries in order to have a platform for a progressive harmonization of arrhythmia treatment. As a result, two EHRA White Books have been published in 2008 and 2009 based on governmental, insurance, and professional society data. Our aim was to analyse the local differences in the utilization of CRT, based on these surveys. A total of 41 countries provided enough data to analyse years 2006-2008. Significant differences were found in the overall number of implantations and the growth rate between 2006 and 2008. Other contributing factors include local reimbursement of CRT, the existence of national guidelines, and a high number of conventional implantable cardioverter-defibrillator implantations, while GDP or healthcare spending has less effect. Focusing on improving these factors may increase the availability of CRT in countries where it is currently underutilized.

KW - Cardiac resynchronization therapy

KW - Europe

KW - Implantable cardioverter-defibrillator

KW - Pacemaker

KW - Reimbursement

UR - http://www.scopus.com/inward/record.url?scp=77951959670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951959670&partnerID=8YFLogxK

U2 - 10.1093/europace/euq041

DO - 10.1093/europace/euq041

M3 - Article

C2 - 20200017

AN - SCOPUS:77951959670

VL - 12

SP - 692

EP - 701

JO - Europace

JF - Europace

SN - 1099-5129

IS - 5

ER -